Two ‘Spectacular’ Studies & Other Movement Disorder Updates
Studies on stem cell therapy, GLP-1 drugs, and a new infusion pump are discussed by Professor Diener in this update on movement disorders. Medscape Neurology
#ADA25: BrightGene seeks a partner for Zepbound-beating obesity shot
A Shanghai-based biotech, previously known as a generics and manufacturing player, posted mid-stage results suggesting its incretin drug might be one of the most powerful to have reached the clinic. And the company is looking …
More people staying on a GLP-1 for weight loss after one year
Post Content
BTSG Raises 2025 Financial Outlook: What’s Backing It?
BrightSpring Health Services, Inc. BTSG has raised its full-year 2025 financial outlook. The company now expects total revenues to be in the range of $12.0-$12.5 billion (up from $11.6-$12.1 billion), representing year-over-year growth of 19.1-24.1%. Adjusted EBITDA is now projected to be in the band of $570-$585 million (up from $545-$560 million), implying a robust […]
#ADA25: BrightGene seeks a partner for Zepbound-beating obesity shot
A Shanghai-based biotech, previously known as a generics and manufacturing player, posted mid-stage results suggesting its incretin drug might be one of the most powerful to have reached the clinic. And the company is looking …
The bold moves to reach more patients according to 10 pharm execs
Becker’s asked pharmacy executives from hospitals and health systems across the U.S. to share what their system has done to expand their access to care. The 10 executives featured in this article are all speaking at the Becker’s Healthcare Fall Chief Pharmacy Officer Summit, from Nov. 5-6, 2025 at the Hilton Chicago. To learn more […]
STAT+: FDA probes deaths of boys taking Sarepta Duchenne drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, I hope you’re able to stay cool wherever you are. Let’s get into the news today. The need-to-know this morning Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called […]
GLP-1 is reshaping consumer’s nutritional needs. So how can brands capitalize?
IFF recently released a report that paints the current GLP-1 consumer landscape. The rise of GLP-1 medications has significantly impacted consumption – and if brands don’t get on board and capture the market share, they risk missing out on a golden opportunity, says IFF.
‘No Way In Hell We’re Gonna Cave On’ said by HIMS CEO’s during his first public response after Novo Nordisk Breakup.
“There’s just no way in hell we’re going to cave on that, no matter who the pharma company is or what the partnership looks like,” as commented by the CEO, Andrew Dudum, after Novo Nordisk terminated their partnership over alleged “deceptive marketing.” He dismissed Novo’s claims and stated that it was misleading. Claiming that the […]
‘Twincretin’ Weight Loss Scales Up Cardiometabolic Gains
A post hoc analysis of the SRMOUNT-1 study finds weight loss from the use of tirzepatide was associated with strong benefits in measures of cardiometabolic health. Medscape Medical News